Autolus Therapeutics to Report Second Quarter 2020 Financial Results and Host Conference Call on August 6
30 juil. 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, July 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics presents new preclinical data during the Virtual 2020 AACR Annual Meeting
22 juin 2020 07h00 HE
|
Autolus Therapeutics plc
- AUTO5 in T cell lymphoma – new in vitro and in vivo data presented demonstrating highly selective targeting of TRBC2 by a novel CAR T candidate - AUTO6NG in small cell lung cancer – in vitro and in...
Autolus Therapeutics presents AUTO1 and AUTO3 data at the 2020 EHA25 Virtual Congress
12 juin 2020 02h30 HE
|
Autolus Therapeutics plc
Pivotal AUTO1 study in adult ALL patients enrolling - AUTO1 continued favorable safety profile and high level of clinical activity, pivotal Phase 1b/2 AUTO1-AL1 program in adult ALL initiated and...
Autolus Therapeutics reschedules its investor EHA conference call
08 juin 2020 17h00 HE
|
Autolus Therapeutics plc
LONDON, June 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program
29 mai 2020 07h37 HE
|
Autolus Therapeutics plc
– Data continue to show encouraging clinical activity alongside tolerable safety to deliver a potentially highly differentiated product profile – Conference call and webcast to be held Monday, June...
Autolus Therapeutics to host Investor Conference Calls through June
26 mai 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 26, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Notice of Annual General Meeting (AGM) on Thursday, June 18, 2020
22 mai 2020 07h00 HE
|
Autolus Therapeutics plc
LONDON, May 22, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today posted...
Autolus Therapeutics to Present New Data at the Virtual 2020 AACR Annual Meeting
15 mai 2020 11h20 HE
|
Autolus Therapeutics plc
- Preclinical data on AUTO5 in T cell lymphoma and solid tumor data on AUTO6NG in small cell lung cancer and AUTO7 in prostate cancer - Conference Call and Webcast to be held Thursday, June 25,...
Autolus Therapeutics to Present New Data on AUTO1 and AUTO3 at the 2020 EHA Annual Meeting
15 mai 2020 07h00 HE
|
Autolus Therapeutics plc
– Data builds on positive data presented at American Society of Hematology in December 2019 and EHA-EMBT 2nd European CAR T Cell Meeting in February 2020 – Conference Call and Webcast to be held...
Autolus Therapeutics to Present New Data on AUTO3 during the ASCO20 Virtual Scientific Program
14 mai 2020 07h00 HE
|
Autolus Therapeutics plc
- Virtual oral presentation will include additional patient data as well as longer term data on previously treated patients - Conference Call and Webcast to Be Held Monday, June 1, 2020 at 8:30...